Advanced Tissue Sciences
This article was originally published in The Gray Sheet
Executive Summary
FDA requests clarification and additional information from ATS regarding its premarket approval application for Dermagraft for the treatment of diabetic foot ulcers, according to a Feb. 21 company release. The PMA was submitted in August 2000. Upon approval, Dermagraft will be marketed by Smith & Nephew (1"The Gray Sheet" Aug. 28, 2000, In Brief)
You may also be interested in...
Advanced Tissue Sciences
Firm announces submission of a premarket approval application to FDA for its Dermagraft wound dressing to treat diabetic foot ulcers. Clinical trials for the Dermagraft, which will be marketed by Smith & Nephew, indicate that the product heals significantly more ulcers than control treatment, the firm says in an Aug. 25 release. Competitor Organogenesis received an approvable recommendation from FDA's General and Plastic Surgery Devices panel in May (1"The Gray Sheet" May 15, 2000, p. 8)
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.